Aclarion Authorizes $2.5 Million Share Repurchase Program to Enhance Shareholder Value

Aclarion, Inc. announced that its Board of Directors has authorized a share repurchase program of up to $2.5 million of the company's outstanding common stock. The commercial-stage healthcare technology company, which leverages biomarkers and proprietary augmented intelligence algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain, expects to execute the repurchase program over the next 12 months. The timing, volume, and nature of repurchases will be determined by the company based on factors including market conditions, share price, liquidity, and operational and strategic priorities.

Chief Executive Officer Brent Ness stated that the authorization underscores the company's commitment to disciplined capital allocation and belief that Aclarion's current valuation does not fully reflect the strength of its platform and long-term growth opportunity. "We believe our shares represent a compelling value at current levels, and we view this program as a flexible and opportunistic tool to enhance shareholder value while continuing to invest in the clinical adoption and expansion of Nociscan," Ness explained. The company intends to fund the repurchase program using existing cash and cash equivalents, with approximately $19.0 million available as of March 31, 2026.

Chief Financial Officer Greg Gould emphasized the company's focus on balancing investment in growth with prudent capital management. "Given our current capital position and expected operating needs, we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility necessary to execute on our strategic priorities," Gould said. Management believes the current cash position provides sufficient runway to support operations through key upcoming milestones, including the initial milestone of the CLARITY randomized trial. For more information about the company's technology platform, visit https://www.aclarion.com.

Repurchases under the program may be made from time to time, in amounts, at prices, and at such times as the company deems appropriate, subject to market conditions and other considerations, in compliance with applicable federal and state securities laws. The program does not obligate the company to acquire any specific number of shares and may be suspended, modified, or discontinued at any time. Repurchases may be executed through various methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or pursuant to Rule 10b5-1 trading plans.

The announcement represents a strategic move by Aclarion to deploy capital while maintaining focus on its core business of addressing the chronic low back pain market with Nociscan. The platform is described as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. By utilizing magnetic resonance spectroscopy data from MRI machines and proprietary algorithms to analyze chemical biomarkers associated with disc pain, Nociscan provides physicians with critical insights to optimize treatment strategies. The latest news and updates relating to the company are available in its newsroom at https://tinyurl.com/aconnewsroom.